These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 1973947)

  • 1. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT; Wachtel SR; Galloway MP; White FJ
    J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups.
    Moody CA; Spear LP
    Psychopharmacology (Berl); 1992; 107(1):39-49. PubMed ID: 1350350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
    White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ
    Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
    Hu XT; Brooderson RJ; White FJ
    Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study.
    Hu XT; Wang RY
    J Neurosci; 1988 Nov; 8(11):4340-8. PubMed ID: 2972814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microiontophoretic studies of the effects of D-1 and D-2 receptor agonists on type I caudate nucleus neurons: lack of synergistic interaction.
    Shen RY; Asdourian D; Chiodo LA
    Synapse; 1992 Aug; 11(4):319-29. PubMed ID: 1354398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
    Subramaniam S; Lucki I; McGonigle P
    Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
    Jiang LH; Kasser RJ; Altar CA; Wang RY
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats.
    Robertson GS; Fine A; Robertson HA
    Brain Res; 1991 Jan; 539(2):304-11. PubMed ID: 1675908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
    Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.